Previous Close | 5.82 |
Open | 5.67 |
Bid | 2.32 x 1000 |
Ask | 6.11 x 1100 |
Day's Range | 5.67 - 5.94 |
52 Week Range | 5.25 - 15.78 |
Volume | |
Avg. Volume | 26,564 |
Market Cap | 235.023M |
Beta (5Y Monthly) | 1.00 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.33 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for IVA
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape by Dr. Stephen HarrisonPresentation by Dr. Michael Cooreman of three scientific abstracts from NATIVE selected for poster presentations at the EASL International Liver Congress™ 2022 Update on LEGEND, Inventiva’s Phase IIa combination study with lanifibranor and SGLT2 inhibitor empagliflozin in pati
Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the reduction of the FastTM score in association with the beneficial effects of lanifibranor on liver histology and biologically relevant biomarkers, in patients with NASH and F2/F3 fibrosis.the identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with lanifibran